Seventh US Patent Issued to Analytical Spectral Devices, Inc. Related to Verification of Pharmaceuticals:


Analytical Spectral Devices, Inc. (ASD), manufacturer of precision analytical instruments for real-time, field based material identification and verification, announced today that the United States Patent and Trademark Office has issued Patent Number 7,006,214 related to ASD’s innovative solution, RxSpec® technology.

Boulder, Colo., March 10, 2006 — Analytical Spectral Devices, Inc. (ASD), manufacturer of precision analytical instruments for real-time, field based material identification and verification, announced today that the United States Patent and Trademark Office has issued Patent Number 7,006,214 related to ASD’s innovative solution, RxSpec® technology.

“This is ASD’s seventh patent covering pharmaceutical verification and the second patent specifically related to our RxSpec® drug verification solution” says Dave Rzasa, President and CEO. “These patents further strengthen ASD’s leadership position in providing solutions to furthering pharmacist productivity, while at the same time combating counterfeits.”

ASD’s patented RxSpec® technology utilizes a combined visible and near infrared spectroscopy inspection system to directly check the prescription drug while in the dispensing vial. The real-time measurement is sensitive to chemical composition, color, and dosage level. The measured “chemical fingerprint” is compared to an extensive known database, thereby providing absolute assurance that the dispensed drug is correct in both type and concentration, regardless of similarity in appearance. In seconds, RxSpec® technology verifies the identity and dosage of a prescription drug dispensed by a pharmacy, thereby reducing potentially harmful filling errors, as well as detecting counterfeit drugs. And because RxSpec® technology is non-destructive, it can be used to inspect 100% of the prescriptions prepared by a pharmacy.